<DOC>
	<DOCNO>NCT01217073</DOCNO>
	<brief_summary>The purpose study assess hypothesis treatment study medication ( omarigliptin ; MK-3102 ) provide great reduction A1C Hemoglobin ( marker diabetic severity ) compare placebo , 12 week treatment . The study evaluate 5 different dos omarigliptin identify dose effective treatment type 2 diabetes .</brief_summary>
	<brief_title>A Dose-Range Finding Study Participants With Type 2 Diabetes ( MK-3102-006 )</brief_title>
	<detailed_description>MK-3102-006-Ext 1 add 66-week extension base study ( MK-3102 P006 ) ass long-term safety tolerability omarigliptin . To eligible extension , participant must complete double-blind base study , must least 75 % compliance study drug base study meet criterion discontinuation . Participants randomize placebo base study switch blind manner pioglitazone 30 mg daily , extension study prior implementation amendment P006-13 . Once amendment P006-13 IRB/IEC approve blinded metformin drug supply available site , participant switch pioglitazone metformin , start 500 mg daily titrated 1000 mg twice daily . Participants contraindication metformin discontinue study . Participants randomize 0.25 mg , 1 mg , 3 mg , 10 mg omarigliptin base study switch omarigliptin 25 mg ; randomize 25 mg omarigliptin base study continue dose extension study . After clinical dose omarigliptin select development identify base upon result base study , participant randomize omarigliptin switch identify clinical dose .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>The prospective participant must meet , least , criterion ( among others determine study staff ) eligible study participation . The participant : Has type 2 diabetes mellitus 18 70 year age ; Japan , 20 70 year age ; Has body mass index ( BMI ) &gt; 20 kg/m^2 &lt; 43 kg/m^2 ; Japan : BMI &gt; 18 kg/m^2 &lt; 43 kg/m^2 ; Is currently antihyperglycemic agent ( AHA ) medication ( â‰¥ 14 week ) oral AHA therapy inadequate glycemic control ; Is male , female highly unlikely conceive . If prospective participant meet criteria ( among others determine study staff ) NOT eligible study participation . The participant : Has history type 1 diabetes mellitus history ketoacidosis ; Is weight loss program start weight loss medication within prior 8 week ; Has require insulin therapy within 14 week prior sign informed consent ; Has medical history active liver disease ( nonalcoholic hepatic steatosis ) , include chronic active hepatitis B C , cirrhosis , symptomatic gallbladder disease ; Has congestive heart failure new worsening sign symptom coronary heart disease ; Had follow disorder within past 3 month : acute coronary syndrome , coronary artery intervention , stroke transient ischemic neurological disorder ; Has history malignancy clinically important hematological disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>